04:33 PM EDT, 07/30/2026 (MT Newswires) -- Andrew Callos, Executive Vice President, Chief Commercial Officer, on July 30, 2026, sold 14,000 shares in Cytokinetics ( CYTK ) for $1,118,320. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1061983/000106198326000086/xslF345X05/form4.xml